These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35747845)

  • 1. Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
    Kutsch N; Pallasch C; Decker T; Hebart H; Chow KU; Graeven U; Kisro J; Kroeber A; Tausch E; Fischer K; Fink AM; Wendtner CM; Ritgen M; Stilgenbauer S; Zhang D; Li B; Jürgensmeier JM; Rajakumaraswamy N; Bhargava P; Hallek M; Eichhorst B
    Hemasphere; 2022 Jun; 6(6):e729. PubMed ID: 35747845
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
    Danilov AV; Herbaux C; Walter HS; Hillmen P; Rule SA; Kio EA; Karlin L; Dyer MJS; Mitra SS; Yi PC; Humeniuk R; Huang X; Zhou Z; Bhargava P; Jürgensmeier JM; Fegan CD
    Clin Cancer Res; 2020 Jun; 26(12):2810-2818. PubMed ID: 32156743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
    Kutsch N; Pallasch C; Tausch E; Böhme V; Ritgen M; Liersch R; Wacker A; Jacobs G; Trappe RU; Dreger P; Fischer K; Fink AM; Stilgenbauer S; Zhai S; Li B; Jürgensmeier JM; Rajakumaraswamy N; Bhargava P; Hallek M; Eichhorst BF
    Hemasphere; 2022 Apr; 6(4):e692. PubMed ID: 35284802
    [No Abstract]   [Full Text] [Related]  

  • 4. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
    J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
    Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Morabito F; Gentile M; Seymour JF; Polliack A
    Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
    Chung C; Lee R
    Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab.
    Smolej L
    Pharmgenomics Pers Med; 2015; 8():1-7. PubMed ID: 25691812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
    Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
    Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
    Leblond V; Aktan M; Ferra Coll CM; Dartigeas C; Kisro J; Montillo M; Raposo J; Merot JL; Robson S; Gresko E; Bosch F; Stilgenbauer S; Foà R
    Haematologica; 2018 Nov; 103(11):1889-1898. PubMed ID: 29976743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.
    Munakata W; Ando K; Yokoyama M; Fukuhara N; Yamamoto K; Fukuhara S; Ohmachi K; Mishima Y; Ichikawa S; Ogiya D; Aoi A; Hatsumichi M; Tobinai K
    Int J Hematol; 2023 Apr; 117(4):553-562. PubMed ID: 36576659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
    Furman RR; Sharman JP; Coutre SE; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn I; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Stilgenbauer S; Cramer P; Aiello M; Johnson DM; Miller LL; Li D; Jahn TM; Dansey RD; Hallek M; O'Brien SM
    N Engl J Med; 2014 Mar; 370(11):997-1007. PubMed ID: 24450857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic Options for "Slow go" Patients with Chronic Lymphocytic Leukemia].
    Smolej L
    Klin Onkol; 2015; 28 Suppl 3():3S30-8. PubMed ID: 26489499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia.
    Nair KS; Cheson B
    Ther Adv Hematol; 2016 Apr; 7(2):69-84. PubMed ID: 27054023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
    Cheson BD
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.